The Critical Role of Humanitarian Donations

The Critical Role of Humanitarian Donations

Though humanitarian donations are clearly not the only answer to the complex challenges facing the global oncology community, they do have a critical role to play in reducing inequities in care and extending the lives of certain populations whose local economies and health systems remain years or decades away from facilitating solutions on their own.

In a recent commentary published in the Journal of Global Oncology, co-authors Pat Garcia-Gonzalez MA, Gilberto Lopes MD, Erin Schwartz MSW, and Lawrence Shulman MD, clearly outline the need and efficacy of humanitarian donation programs using lessons learned from the success of joint access initiatives between Novartis and The Max Foundation.

In addition to providing concrete evidence for the need and efficacy of humanitarian donation programs, the paper also demonstrates the terrible human cost that would result from their absence. Garcia-Gonzalez and her co-authors write:

“…in this era of globalization, we are leaving our friends behind and they know it. There is only one thing worse than hearing your loved one is diagnosed with cancer. It is to be told that there is a treatment that could help, but because of the place where you live, your loved one cannot access it and will therefore die a premature and avoidable death.”

Read the full paper here

Read Pat Garcia-Gonzalez’s LinkedIn article

Make a donation to expand treatment access

The Max Foundation is a leading global health nonprofit organization dedicated to accelerating health equity. For 28 years, Max has pioneered practical, scalable, high-quality solutions to bring life-extending treatments and patient-centered health care to more than 100,000 people living with cancer and critical illness in low- and middle-income countries. Max believes in a world where all people can access high-impact medicines, where geography is not destiny, and where everyone can strive for health with dignity and with hope.

Related Articles

  • CMLPath to Care

    CMLPath to Care

    In 2017 The Max Foundation, through its subsidiary MaxAid, and Novartis have renewed their commitment to patients by launching CMLPath to Care™ a new collaboration aimed at providing humanitarian access to treatment for CML and other rare cancers for those patients for whom no other form of local treatment access exists today. CMLPath to Care consists of humanitarian product donations and funding support from Novartis to Max, and an innovative new distribution model developed and implemented by Max and its international distributor, under the Max Access Solution umbrella.

  • Spot On CML Grows in the Philippines

    Spot On CML Grows in the Philippines

    Today, Spot On CML is active in 19 countries and, on June 29th, 17 patients were chosen by the treating physicians at Philippine General Hospital to take part in the program. While CML testing is available in the Philippines, it’s prohibitively expensive – placing critical diagnostic information out of reach for many patients.

  • My PCR Releases New Resource on Treatment Free Remission (TFR)

    My PCR Releases New Resource on Treatment Free Remission (TFR)

    My PCR has released a new FAQ about Treatment Free Remission (TFR) – a potential treatment goal for some patients living with chronic myeloid leukemia (CML).